Doug Levinson, PhD, Partner Doug joined Flagship in 2006, bringing to Flagship’s venture investment and new venture creation activities over fifteen years of experience in the biotech industry. Prior to Flagship, Doug was with TransForm Pharmaceuticals since 2000 as part of its scientific founding-team joining Professors Bob Langer and Michael Cima of MIT. Most recently, he was Vice President of Emerging Science and Technology and led the design, development and implementation of TransForm's basic technology platforms and business model. TransForm was acquired by Johnson & Johnson for $230 million in 2005.
Prior to TransForm, Doug was with Millennium Pharmaceuticals, which he joined as a founding scientific team member. At Millennium for seven years, Doug was responsible for establishing the company's early scientific program in Immunology/Inflammation, which he grew to the largest research effort at Millennium with a staff of 170 researchers. Before joining Millennium, he was with Creative Biomolecules where he was responsible for the generation of synthetic single-chain antibody molecules.
Doug holds a Ph.D. in Genetics from Harvard University and a B.S. cum laude in Molecular Biology from the University of Massachusetts. He has authored numerous patents in the field of high throughput platform technologies and molecular genetics and has published extensively in scientific journals.
At Flagship, Doug is a member of the investment team and focuses on early-stage companies in the biotech industry. He is currently a Director of T2 Biosystems after serving as Founding CEO, and is on the Board of Resolvyx.
| 
